Skip to main
TMDX
TMDX logo

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 50%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group Inc. has demonstrated strong performance in the transplants market, with significant year-over-year quarterly growth in donation after circulatory death (DCD) organs, particularly a 44% increase in DCD livers and a 15% increase in DCD hearts. The overall transplant volume trends indicate healthy growth, supported by a 9% month-over-month increase in DCD organs, which contributed to a combined 7% growth in the heart, liver, and lung market quarter-to-date. Future prospects appear promising with anticipated product launches and a potential revenue forecast for 4Q24 exceeding $120 million, suggesting a positive trajectory for the company’s financial performance.

Bears say

TransMedics Group Inc. has exhibited concerning trends in organ transplant volumes, with donor brain-dead (DBD) livers and hearts declining 6% year-over-year and 13% month-over-month, which could impact the company’s growth potential in the transplantation market. Despite a slight increase in revenue estimates for 2026 to $657 million, the group’s valuation multiples have decreased from 7.2x to 6.8x for 2025 EV/Sales, indicating a diminishing investor sentiment. Additionally, challenges such as competition from other technologies, potential reimbursement changes, and regulatory risks could adversely affect the adoption rate of TransMedics' proprietary organ care systems, contributing to an overall negative outlook for the company's stock.

TMDX has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 50% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 10 analysts, TMDX has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $123.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $123.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.